Bionano Q2 2026 revenue up 21% to $8.2M; fully retires secured convertible debentures

Bionano Genomics, Inc.

Q2 revenue $8.2M, up 21% YoY from $6.7M; consumables revenue $4.3M, up 31%.
Sold 9,219 flow cells (+27% YoY); gross margin 53% vs 52% in Q2 2025.
Operating expenses $11.5M (+2%); adjusted operating expense $8.7M (-2%).
Completed full retirement of all Senior Secured Convertible Debentures, releasing asset liens.
Alex Hastie returned as Chief Scientific Officer; T-ALL study showed OGM detected abnormalities in 97.8% of cases vs 55% by karyotyping.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.